← Back to Clinical Trials
Recruiting NCT06085690

NCT06085690 Multicenter Clinical Translational Study of "ICU-NO CRBSI" Based on Improvement Science

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06085690
Status Recruiting
Phase
Sponsor Fudan University
Condition CRBSI - Catheter Related Bloodstream Infection
Study Type INTERVENTIONAL
Enrollment 8,050 participants
Start Date 2023-09-04
Primary Completion 2025-09-30

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type INTERVENTIONAL
Interventions
evidence-based intervention Plan for the Prevention of CRBSI in ICU patients

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 8,050 participants in total. It began in 2023-09-04 with a primary completion date of 2025-09-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this type of study is to construct the continuous quality promotion project "ICU-NO CRBSI(Catheter-Related Bloodstream Infection , CRBSI)" based on improvement science, and to verify its effect in the prevention of central venous catheter-related bloodstream infection and continuous quality improvement in ICU ( Intensive Care Unit , ICU) through multi-center implementation and two rounds of improvement. The main question\[s\] it aims to answer are: What is the incidence of catheter-related bloodstream infection in the ICU of participating units? How compliant are health care providers in the ICU with evidence-based sensory control practices for the prevention of catheter-associated bloodstream infection? Participants will be provided with the hospital's routine CVC (Central Venous Catheter ,CVC) care practices and CVC quality improvement measures based on evidence-based guidelines What technical and cultural support is needed to implement quality and safety improvement measures?

Eligibility Criteria

Inclusion Criteria: * ICU stay over 48 hours * CVC was placed for more than 24 hours Exclusion Criteria: * Pregnant patients * Patients with a history of CRBSI infection * Patients with central venous catheterization were brought in from other hospitals

Contact & Investigator

Central Contact

CHUNLEI Li

✉ 21211170023@m.fudan.edu.cn

📞 15800488689

Principal Investigator

Yan Hu

STUDY CHAIR

School of Nursing, Fudan University; Center for Evidence-based Nursing, Fudan University

Frequently Asked Questions

Who can join the NCT06085690 clinical trial?

This trial is open to participants of all sexes, studying CRBSI - Catheter Related Bloodstream Infection. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06085690 currently recruiting?

Yes, NCT06085690 is actively recruiting participants. Contact the research team at 21211170023@m.fudan.edu.cn for enrollment information.

Where is the NCT06085690 trial being conducted?

This trial is being conducted at Shanghai, China.

Who is sponsoring the NCT06085690 clinical trial?

NCT06085690 is sponsored by Fudan University. The principal investigator is Yan Hu at School of Nursing, Fudan University; Center for Evidence-based Nursing, Fudan University. The trial plans to enroll 8,050 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology